Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group repor
about
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group ReportContent Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.The lung function score and its components as predictors of overall survival and chronic graft-vs-host disease after allogeneic stem cell transplantation.Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host diseaseEfficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.Biomarker Panel for Chronic Graft-Versus-Host Disease.How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantationComparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.Evolving concepts in prognostic scoring of chronic GvHD.Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.Ocular surface analysis in hematological patients before and after allogeneic hematopoietic stem cell transplantation: implication for daily clinical practice.Classification systems for chronic graft-versus-host disease.Novel targets in the treatment of chronic graft-versus-host disease.Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide.An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.Translation, Cross-Cultural Adaptation, and Validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in a Brazilian Population.Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.Chronic graft-vs-host disease in 2016: a major challenge and an opportunity.Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.Additional infusions of mesenchymal stem cells improve response rate in multidrug-resistant GvHD patients.Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center.Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.B-cell targeting in chronic Graft-versus-Host disease.Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials.Cytokine mediators of chronic graft-versus-host disease.Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study.High MDR-1 expression by MAIT cells confers resistance to cytotoxic but not immunosuppressive MDR-1 substratesHow ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHDThe eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial
P2860
Q26827651-B9677892-89CD-44C7-9E35-894E5987ADDCQ30749782-386A25CB-2203-4578-AC8B-8A6A80B89B92Q33625948-F3C21A32-D5E7-42E5-9EBD-F3CFA0AB6083Q36443116-022E1AD3-73E9-4CB8-944D-9B2E49E32BC6Q36707835-9DB6A5E4-683A-49CB-A178-5C78DC541A9AQ36708947-4FEDB766-65BF-470E-A4B0-548084775606Q36712018-629DF2B7-D530-40B4-ABA1-D17F3B39E0ECQ37075998-FD3B16FE-656A-4FCC-9C00-07A28D1D5932Q37076418-98F00C07-8A23-4E65-8025-2A025D958CCFQ37234820-AA04E240-6BF7-4FC7-9B2C-ED1329D4876EQ37609903-AE03FDD2-33ED-4DA5-B349-700B51FFB4CBQ38388775-F8FF7536-FF4D-4C34-AFA8-06F8BB0FF821Q38739174-E7AC33B2-CCFB-46DC-A76D-A2B2CD20AB75Q38753771-C0B37276-A4DA-4184-BDFB-0B2C02E25894Q38774962-EB52E074-9DC7-4153-899F-D1E7187E64C7Q39002161-E58B596C-066E-4428-B6E4-F31942AB9A77Q39023963-5EFEC132-0543-40AA-AD01-FCFE01C64B12Q39084186-7B720992-4FE4-4EC7-A400-26A446A67DCEQ40204811-A7FB20C4-D598-480C-9FF9-CE09740DF223Q41529149-3E1185B4-8C8E-4809-A651-EDFB32BBA808Q42768766-052D469B-B680-47FE-BE9E-3534E92BF078Q42943825-C869DD71-FF6B-4899-925A-E045C68DAF24Q46428638-66C71565-02A0-43CC-A395-95C4C8A940DDQ48135558-047C56E3-2EE5-4EAF-AAF3-D9DA652101B9Q48251531-EB90DAC3-E89B-4D3E-BA0A-EFDA7D6D4F23Q49724160-000C1562-A586-4116-8F35-1B96DC809467Q50044417-11BDCD39-F950-4222-9BAD-D02FA8C253ECQ50115590-ACD99EE1-092A-4A5D-AFA5-E3BC921C3A5BQ50915048-5AD2B6F3-F823-4B2A-985C-B81D577EF66DQ52687293-4E7E7E11-EAF2-4FAE-955B-CFEAE173C387Q58714915-7FD03672-00B9-4C72-8662-06A848B00820Q58782275-61A81DFA-D74E-4086-A280-77F214BF17D6Q58793818-04408F27-B4A6-426A-BD95-89557669605B
P2860
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group repor
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Measuring therapeutic response ...... e Criteria Working Group repor
@ast
Measuring therapeutic response ...... e Criteria Working Group repor
@en
type
label
Measuring therapeutic response ...... e Criteria Working Group repor
@ast
Measuring therapeutic response ...... e Criteria Working Group repor
@en
prefLabel
Measuring therapeutic response ...... e Criteria Working Group repor
@ast
Measuring therapeutic response ...... e Criteria Working Group repor
@en
P2093
P2860
P1476
Measuring therapeutic response ...... e Criteria Working Group repor
@en
P2093
Anita Lawitschka
Anne M Hall
Attilio Olivieri
Carrie Kitko
Daniel Wolff
David Jacobsohn
Donna Przepiorka
Fiona Dignan
Georgia Vogelsang
Iskra Pusic
P2860
P304
P356
10.1016/J.BBMT.2015.02.025
P577
2015-03-19T00:00:00Z